NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/15/2026 10:20
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,981.26 mln
Float134 mln
Earnings Date08/06/2026
Piotroski F-Score
4
/ 9
Borderline
Beneish M-Score
-2.65
Likely reliable
1-Year Forecast
26.55
Transformational upside
Relative Strength
82
/ 100
Strongly outperforming
Debt / Equity
0.13
Very low leverage
ROE
-55.80
Deeply negative
Business Description
Intellia Therapeutics is a Cambridge, Massachusetts-based company founded in 2014 that develops treatments designed to permanently correct disease-causing genetic errors in the human body. Its own pipeline includes two early-stage clinical programs targeting rare conditions ? a protein-buildup disorder affecting the heart and nerves, and a condition that causes severe recurring swelling. Beyond its internal work, Intellia partners with several biotechnology companies to advance a range of cell-based therapies for cancer, autoimmune diseases, and cystic fibrosis.
